BR9709902A - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors

Info

Publication number
BR9709902A
BR9709902A BR9709902A BR9709902A BR9709902A BR 9709902 A BR9709902 A BR 9709902A BR 9709902 A BR9709902 A BR 9709902A BR 9709902 A BR9709902 A BR 9709902A BR 9709902 A BR9709902 A BR 9709902A
Authority
BR
Brazil
Prior art keywords
matrix metalloproteinase
metalloproteinase inhibitors
inhibitors
matrix
metalloproteinase
Prior art date
Application number
BR9709902A
Other languages
Portuguese (pt)
Inventor
Marco Alpegiani
Francesa Abrate
Pierluigi Bissolino
Massimiliano Palladino
Ettore Perrone
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of BR9709902A publication Critical patent/BR9709902A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9709902A 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors BR9709902A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613547.0A GB9613547D0 (en) 1996-06-27 1996-06-27 Matrix metalloproteinase inhibitors
PCT/EP1997/003251 WO1997049674A1 (en) 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR9709902A true BR9709902A (en) 1999-08-10

Family

ID=10796022

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709902A BR9709902A (en) 1996-06-27 1997-06-20 Matrix metalloproteinase inhibitors

Country Status (18)

Country Link
EP (1) EP0920414A1 (en)
JP (1) JP2000514043A (en)
KR (1) KR20000022534A (en)
AR (1) AR008621A1 (en)
AU (1) AU733938B2 (en)
BR (1) BR9709902A (en)
CA (1) CA2257404A1 (en)
CZ (1) CZ430398A3 (en)
EA (1) EA001432B1 (en)
GB (1) GB9613547D0 (en)
ID (1) ID17792A (en)
IL (1) IL127262A0 (en)
NO (1) NO986049L (en)
NZ (1) NZ333550A (en)
PL (1) PL330897A1 (en)
TW (1) TW460441B (en)
WO (1) WO1997049674A1 (en)
ZA (1) ZA975631B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (en) * 1997-05-13 1998-11-19 Hoechst Ag Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids
KR100352316B1 (en) 1997-07-31 2002-09-12 더 프록터 앤드 갬블 캄파니 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
GB9803005D0 (en) * 1998-02-12 1998-04-08 British Biotech Pharm Anti-inflammatory agents
GB9804777D0 (en) * 1998-03-07 1998-04-29 British Biotech Pharm Anti-inflammatory agents
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
GB9901863D0 (en) 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
KR20010102486A (en) 1999-03-03 2001-11-15 데이비드 엠 모이어 Alkenyl- and alkynyl-containing metalloprotease inhibitors
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
JP4314340B2 (en) 2001-06-15 2009-08-12 ヴィキュロン ファーマシューティカルズ インコーポレイテッド Pyrrolidine bicyclic compound
AR036053A1 (en) 2001-06-15 2004-08-04 Versicor Inc N-FORMIL-HYDROXYLAMINE COMPOUNDS, A PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
KR20060116552A (en) * 2005-05-10 2006-11-15 연세대학교 산학협력단 N-formyl hydroxylamine derivatives as matrix metalloproteinase inhibitors
FR2949463B1 (en) * 2009-08-26 2011-09-16 Commissariat Energie Atomique MMP INHIBITORS
JP5863663B2 (en) 2009-11-12 2016-02-16 ファーマトロフィックス, インコーポレイテッド Crystal forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (en) * 1986-03-11 1987-09-12 Hoffmann La Roche hydroxylamine
JPH05503720A (en) * 1990-12-03 1993-06-17 セルテック リミテッド Peptidyl derivative
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives

Also Published As

Publication number Publication date
AU3342297A (en) 1998-01-14
IL127262A0 (en) 1999-09-22
NZ333550A (en) 2000-07-28
ID17792A (en) 1998-01-29
EA199900057A1 (en) 1999-06-24
JP2000514043A (en) 2000-10-24
PL330897A1 (en) 1999-06-07
CA2257404A1 (en) 1997-12-31
AR008621A1 (en) 2000-02-09
GB9613547D0 (en) 1996-08-28
EP0920414A1 (en) 1999-06-09
AU733938B2 (en) 2001-05-31
EA001432B1 (en) 2001-02-26
NO986049D0 (en) 1998-12-22
KR20000022534A (en) 2000-04-25
CZ430398A3 (en) 1999-08-11
ZA975631B (en) 1998-01-30
TW460441B (en) 2001-10-21
NO986049L (en) 1999-03-01
WO1997049674A1 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
BR9509802A (en) Matrix metalloprotease inhibitors
PT936912E (en) CISTEIN PROTEASE INHIBITORS
FI963597A0 (en) Isoprenyylitransferaasi inhibitors
NO972930D0 (en) Fibronectin-adhesion inhibitors
NO995433D0 (en) Protease inhibitors
BR9710381A (en) Matrix metalloprotease inhibitors - phosphinate base
PT979240E (en) SERINE-PROTEASE INHIBITORS
PT958287E (en) SULFAMIDE-METALOPROTEASE INHIBITORS
DK1027332T3 (en) New lactametalloprotease inhibitors
ATE268781T1 (en) THROMBIN INHIBITORS
BR9709902A (en) Matrix metalloproteinase inhibitors
NO995434L (en) protease inhibitors
NO995435D0 (en) Protease inhibitors
PT886647E (en) SERINE-PROTEASE INHIBITORS
NO995268D0 (en) protease inhibitors
BR9707086A (en) Asparta proteinase inhibitors
PT1047665E (en) MATRIX METALOPROTEASE INHIBITORS
DE69733263D1 (en) MARKED ELASTASE INHIBITORS
DE69720957T2 (en) ACE INHIBITORS
DE29820413U1 (en) Hydraulic device
GB9702085D0 (en) Matrix metalloproteinase inhibitors
SI0901466T1 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
ATE228999T1 (en) METALLOPROTEINASE INHIBITORS
GB9714548D0 (en) Matrix metalloproteinase inhibitors
HUP9902606A3 (en) Matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES.